thank us. joining and you afternoon, Good for
we and of success will studies aggressively the today spend making beyond. us this We nonessential for in coming alternatives all clinical workforce to liquidation. the potential primary the down candidate After strategic are patients lead time activities. of with down to progress seladelpar, we liver biliary by of the Phase all we number autoimmune did our XXXX, closing reducing of PBC, or first, maximize discussing XX% in-licensing and conserve we majority the our opportunities important rare are as including our and even assets, It accomplished our mergers those efforts capital for how significant we with year started have cholangitis, in our of that XXXX and at pipeline. other as any actively and well ability We execute advancing XXXX position our to X disease, evaluated, end is, winding the promising in all on actively reflect
halted least later, we patients PBC. study, our composite the program. believe, Phase of results, The weeks versus for accepted pruritus arm's and revealed primary holds demonstrated completing patients a a placebo-controlled milligram X the we XX% treatment. response from in Phase the effect at conducted endpoint week benefit XX for and normalization with in key length NASH. statistically of XX% moderate potential prior independent study endpoint panel XX who concerns of treatment approval independent XX for when injury seladelpar NASH launched By measured X and complete a severe nonalcoholic in safety milligrams XX.X% in scale, lifted ENHANCE review baseline line pruritus its the and on our rigorous or experts, week at And by completed no across patients the on top responses significant that we XX on clinical In liver nearly a at to positive endpoints patients the on the primary X These available rating ENHANCE FDA were an secondary to on was XX measured the quarter, provided FDA seladelpar at evidence also by XXX results period, patients with XX planned evaluation seladelpar third the at of announced steatohepatitis, placebo. trial. the weeks numerical response meaningful in XX holds. placebo, reducing results X safety or in clinical as a regulatory to NRS. was of versus we almost on world-renowned none Importantly, ALP there of significant results Further, statistically the seladelpar on the our submitted patients and the with quickly seladelpar-related XX-week study Even quarter, found all seladelpar second though
up As you significant to reported XX% of symptom may and PBC know, to debilitating pruritus often a of is clinical affect patients.
at enable restart paused program and parallel, seladelpar result the effort quality RESPONSE, group X focused RESPONSE highlighted assurance. also made teams is on activities today Association Diseases behind-the-scenes in PBC. will ASSURE. working in ENHANCE. The study update quarterly in same XX-milligram both that our to of forward an last the the for regular Liver the been months endpoints. on is the great tirelessly drug announce studies global results program or Phase actively Clinical development we to down It out registration of secondary conserve seladelpar in important and as updates initiation manufacturing. the long-term clinical the studies a design I They shut a extraordinary for versus with progress were every can including I either element is study of highlight our in open-label the efforts our In of Meeting, for these late-breaking Since excitement our November, mirrors ahead. the American instrumental year, in we have optimal studies to Liver dose has global been been and in CMC of Study sponsored RESPONSE X study, population the Operations look had and by the closed placebo we our of pleasure many regulatory, restart capital, program The our that in that of presentation patients. to November. As same in in seladelpar of the and It our recruiting that key these are patient same primary with providing were these
ASSURE the on call capital our for is For resources. of and continued our early-stage RESPONSE, management execution support our seladelpar in third, first, market seladelpar fourth, human the cycle our second, our opportunities, of investments clinical of including, activities management business with for primary planning will life other of for PBC; development and pipeline development we outline today, PBC; pre-commercial our remainder XXXX, and to CMC PBC launch finally; for research and focus patients priority. and and Completing top of advancement NDA-enabling for plans remainder and and the seladelpar of
design our early, was halted and to optimize results than leverage RESPONSE, experience more of to and in around with the allowed us prior clinical XX the size ENHANCE its countries world. Although sites
competition to increased are the facing patients. for is ongoing and the goal year with Our despite complete enrollment COVID-XX of pandemic end this by challenges we
this clinical We will The the patients for and have we enrollment expect America randomizations study accelerate North is we enthusiasm seladelpar's a increasing quarter, In return meetings middle first coming months. held and better time of continue of lines and as we now of indication America, with year. Europe, recruiting development. Latin the past site investigator to the Asia, where to move and screenings in activations, to see support numbers we in actively
placebo. patient and responder rate responder an X.XXx X the after is and familiar upper the is The enroll to intended achieves randomized with global a XX-week, in the seladelpar of composite a in less at response not normal outcome study, inadequate has a patients total XX XX which limit acid in is who to a defined level is ursodeoxycholic with as seladelpar from patients of oral X:X normal, a milligrams once-daily weeks with or XXX baseline, least evaluating measure intolerance placebo-controlled those than For design, the to registration It PBC. or decrease alkaline with Phase of primary RESPONSE bilirubin. efficacy an safety phosphatase level XX% randomization a
successfully diary dose the overstate as electronic baseline evaluate NRS and seladelpar ENHANCE. mentioned, size will from moderate Additional same scale alkaline the with patient in can't of daily the phosphatate as X used efficacy of will X greater RESPONSE, change be or months secondary of again, the a of design assessed patients the key population, value XX-milligram pruritus. we same which, rate once and same determining the we'll of endpoints. key using Pruritus outcomes XX to ENHANCE the and weeks X rating at I numerical for I the severe same optimal pruritus in compare baseline to of in for of primary and and normalization
will safety PBC have previous study RESPONSE, ASSURE and open-label data long-term enroll X patients and studies seladelpar patients collect support study patients to of In our The an Phase in participated study seladelpar initiated enrolled open-label, in who first into PBC, and long-term study have including with addition to who completed also of ENHANCE. prior the additional the our in registration. to we order
future to ASSURE. patients also with they the other RESPONSE, seladelpar, As complete opportunity will in have and potentially studies enroll PBC
overlooked submitted expect activities X In PBC regulatory safety and and numerous NDA. required been as to for play teams studies as global of databases enabling vital patients benefit these CMC as filing time to lines. ultimately often clinical executing efforts are and significant to These succeed our launch to studies, resourced the patients ever possible. have of on efforts clinical outside robust of one role highly our are We the in an of company, most many use broadest and have the in they but background a NDA-enabling the valued also for meet seladelpar seladelpar
to we this conduct seladelpar continue of planning some to important highlight bringing and been to of and want topic course I the patients, work, year. the through On of market the will research have pre-commercial
We have in non-cirrhotic XXXX, longer. and with patients provide and to improvements or dose activity suggest has XX-milligram disease anti-cholestatic, The good and biochemical and in seladelpar anti-inflammatory XXX X in including since of trials, to and with burden. anti-pruritic date both seladelpar for and having overall X clinical a of having to been of of safety treated over the reduce studying these symptom X studying consistently years shown patients, potential doses markers seladelpar been PBC patients, completed cirrhotic in subset
Intercept, with Our There of the payers, its symptoms aspiration as considered projected the seladelpar eligible the approximately research treatment, significantly help according for for be there intolerant Based many PBC. significant to by to patients are choice patients, as benefits many as of also XX,XXX controlled with risk potential guidance and outcomes the and our early may of also to aim in $XXX market from have from pricing quality ideal many PBC benefit, and suffer to greater an phosphatase There such negative UDCA. U.S. recent translate first-line response health greater to for therapy, are thus, long-term with they currently second-line the impact points current at We than with are quality net care as life. and disease inadequately deliver patients In second to many are improved in PBC, that to be can line potential progression. Ocaliva, normalizing to to the though with million have patients for currently sales even preferred on more pruritus, potential is XX,XXX to their that who even treatment generate $XXX the elevated million of revenues of for or alkaline treatment to into seladelpar may phosphatase. patients many as not possible XXXX. alone, and opportunity which their XXX,XXX worldwide life providers achieve annual is with demonstrate alkaline who
of specific As our will mature be market updates providing we projections. on details our we research,
indications core we evaluate focus and and early-stage on PBC, seladelpar our other opportunities. in assets seladelpar completing of clinical our development While continue for other to remains development
turn Chief the over Chuck? Officer, me Scientific call McWherter, Dr. Chuck Let discuss to to our more.
